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Erythropoietic protoporphyria (EPP) is associated with a de-
ficiency of proto haem ferrolyase. We have used a novel assay 
for this enzyme based on its ability to utilize zinc as a substrate 
to investigate the inheritance ofEPP in nine affected families. 
Zinc chelatase activity was markedly reduced in peripheral 
blood mononuclear cells from 14 EPP patients (mean, 3.3 
nmol Zn protohaem/h/mg protein; range, 0.3-8.0) when 
compared with 41 controls (16.8 ± 3.6) P < 0.01. In three 
families with parent-to-child transmission of disease, the 
asymptomatic parent had an enzymatic activity within the 
T The final enzyme of the haem synthetic pathway, protohaem-ferrolyase (EC4 . 99.1.1), commonl y knownas haem. synthaseor ferrochelatase, is located on the mner mltochondnal membrane where it cata-lyses the insertion of ferrous iron into the nucleus of 
protoporphyrin IX to form haem. In the uncommon, and occasion-
ally fatal, inherited disorder erythropoietic protoporphyria (EPP), 
the activity of this enzyme is defi cient [1 ,2) and free protoporphyrin 
accumulates, causing marked photosensitivity. The extensive dou-
ble-bond structure of its tetrapyrrole nucleus renders protopor-
phyrin highly photoactive such that absorption of violet energy 
between 400 and 410 nm generates reactive species that are respon-
sible for acute phototoxicity [3) . 
On the basis of biochemical studies and pedigree analysis, the 
inheritance of EPP has been generally assumed to be autosomal 
dominant with variable penetrance [1,4-6). However ferrochel a-
tase activity in tissues obtained from presumed heterozygotes has 
been only 10 to 25% of normal [1 ,2,7,8) and thus considerably 
lower than that expected for an autosomal dominant condition 
showing simple gene-dosage effects. From a study of 91 Dutch 
families with protoporphyria, W ent and Klasen [9J concluded that 
the disorder was transmitted as a recessive character and advanced a 
complex 3-allele hypothesis to account for its inheritance pattern. 
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normal range. In three pedigrees where the parents were 
asymptomatic, enzymatic activities were below the 95 
confidence limits in both. Zinc chelatase activity was below 
the mean control value in 17 of the 18 parents in nine affected 
pedigrees, and six of seven asymptomatic offspring of pa-
tients with protoporphyria. The findings suggest that EPP is 
not transmitted as a simple dominant trait and that inheri-
tance of more than one gene may be required for disease 
expression.] Invest Dermatol 95: 260-263) 1990 
However, in the absence of enzymatic data, the validity of ~ 
analysis has yet to be verified. 
Hitherto assays of ferrohaem-protol yase that have employed irol\ 
as a substrate have been too laborious for general use in diagnosis. 
Following the observation that when the supply of iron for ha~ 
synthesis is limiting in vivo, zinc protohaem is formed and that &~ 
protoporphyrin accumulates in erythropoietic protoporphyria [101, 
we have employed an assay based on the formation of zinc proto-
haem. The assay is easy to use and sensitive enough to allow deter-
mination of haem synthase activity in mononuclear cells obtain 
from 10 ml of peripheral blood. We have, moreover, demonstr.l. 
that zinc chelatase and ferrochelatase activities reside in the samt 
enzyme that is catalytically deficient in EPP [11] . Accordingly, as 
described in this paper, we have further utilized this assay to investi-
gate the genetic transmission of this enzymatic defect in pedigrees 
affected by proto porphyria. 
METHODS 
Subjects Fourteen patients (age 12 to 73 years; four males and 10 
females) wi th EPP attending St. John 'S Hospital for Diseases of rht 
Skin were studied. Diagnosis was made from the classical history : 
skin photosensitivity and the characteristic elevations of protopor-
phyrin concentration in erythrocytes and, occasionally, in stool. 
The homozygous hepatic porphyrias were excluded in each case br 
the clinical picture and the pattern of porphyrin abnormaliti 
T wenty-five unaffected first-degree relatives with a normal bi 
chemical screening test for blood porphyrin (12), including bo 
parents of nine patients, were also recruited. Controls were 1 
healthy vounteers and 22 patients under investigation for diseases 
unassociated with abnormal porphyrin metabolism. Informed con-
sent was obtained from all subjects. 
Assay of Zinc Chelatase The enzyme was measured in periph-
eral blood mononuclear cells as recently described [6]. Mononude 
cells were prepared from samples of venous blood by Ficoll-Paqu 
0022-202X/90/ S03.50 Copyright © 1990 by The Society (or Investigative Dermatology, Inc. 
260 
VOL. 95, NO.3 SEPTEMBER 1990 GENETIC HETEROGENEITY IN ERYTHROPOIETIC PROTOPORPHYRIA 261 
(Pharmacia) density-gradient centrifugation and then sonicated for 
20 sec (10% vlv suspension) in 20 mM Tris buffer, pH 8.0, con-
taining 20% v Iv glycerol, 1 M NaCl, 1 mM dithiothrietol, and 1 % 
cholate. The final assay mixture contained 50 f1M protoporphyrin 
IX (Porphyrin Products, Logan, UT), 200 f1M zinc acetate (Sigma), 
1 mM palmitic acid (Sigma) , and 1 % Triton X-I00. Tissue blanks 
were prepared by incubating mononuclear cell extracts overnight at 
3rC. After stopping the reaction with ethanol, fluorescence at 
590 run was read directly after excitation at 410 nm using a Perkin-
ELmer fluorescent spectrophotometer, Model LS3B. Haem synthase 
acrivity was estimated as nmol zinc protohaem formed in 1 h per mg 
.cellular protein, as determined by the Lowry procedure. 95% confi-
dence limits were derived from the mean ± two SD for the control 
val ues. 
RESULTS 
As previously reported, zinc-chelatase activity was markedly re-
duced in mononuclear cells from all the 14 patients affected by 
protoporphyria (mean, 3.3 nmoljh/ mg protein; range, 0.3-8.0) 
when compared with 41 controls (16.7 ± 3.6 SD) (Fig 1). There 
was no overlap of the values in these two groups. Zinc-chelatase 
activity was reduced below the mean for controls in 17 of 18 par-
ents, eight of nine sib lings of affected individuals, and six of seven 
unaffected offspring of patients (Fig 1). Enzymatic activities in the 
18 parents of nine affected patients are shown (Figs 2 and 3a,b) . The 
measured activity did not correlate with erythrocyte protopor-
phyrin concentration in affected patients . 
DISCUSSION 
It is well known that, as well as disabling photosensitivity, erythro-
poietic protoporphyria may cause fulminating, and usually lethal, 
liver disease [13 ,15]. Given the severity of this complication, the 
development of methods to detect carriers in affected pedigrees 
would clearly be justified , but hitherto no definitive means of iden-
tification has been available. Fecal protoporphyrin excretion, some-
times elevated in EPP sufferers, is generally normal in the parents of 
EPP patients and surveys of red-cell- free protoporphyrin levels in 
affected families have failed to define a predictable pattern of disease 
inheritance [4,9]. 
The introduction of sensitive assays to identify the enzymatic 
protoporphyria may allow the mode of transmission to be examined 
in more precise terms and thus facilitate detection of asymptomatic 
carriers. Bloomer et al [16] investi gated ferrochelatase activity in 
fibroblasts obtained from members of three affected pedigrees: in 
each case one parent had subnormal enzymatic activities and the 
other partner had normal activity. Although this suggests dominant 
transmission of the disorder, consistently very low « 30% control) 
ferrochelatase activities in patients with disease are not readily ex-
plained in a condition that should reflect expression of a single 
mutant allele in heterozygous individuals. To investigate the inher-
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Figure 1. Zinc chelatase activity in peripheral blood mononuclear cells 
obtained from controls (ope/l circles) , patients with erythropoietic protopor-
pbyria (opell triallgles), unaffected siblings (opw squares), and unaffected off-
spring of EPP patients (opell diamollds). 
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Figure 2. Zinc chelatase activity in nine pairs of parents (each pair aligned 
vertica lly) of EPP patients. Opell circles, mothers; opw squares, fathers; solid 
symbols, individuals with symptomatic protoporphyria. 














Figure 3. Representative pedigrees affected by protoporphyria showing 
zinc chelatase ac tivities (nmol Zn protohaemj hj mg protein) suggestive of 
A) autosomal recess ive and B) autosomal dominant transmission. The mean 
control activi ty was 16.7 ± 3.6 nmoljh/ mg protein. 
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itance of erythropoietic proto porphyria, we have developed a sensi-
tive assay for haem synthase that allows detection of the enzymatic 
defect in leukocytes and that can readily be used to screen patients 
and their close relatives . 
With this technique we have identified two distinct patterns of 
inheritance in erythropoietic protoporphyria. Among the 18 par-
ents of nine patients, in three instances one parent of each pair was 
also affected by the disease and had zillc chelatase activity below the 
95% confidence limit of normal; the other, aSy'mptomatic parent 
had normal erythrocyte protoporphyrin screening tests and enzy-
matic activity as expected for autosomal dominant transmission. In 
three other families, zinc chelatase activity was below the 95% 
confidence limit of normal in both parents, each of whom were 
asymptomatic with normal erythrocyte protoporphyrin screening 
tests. This pattern of inheritance suggests autosomal recessive trans-
mission. In the remaining three families, both the parents were 
unaffected and had enzymatic activities within the normal range, 
such that the pattern of inheritance is indeterminate. It is note-
worthy that no preponderance of mother to child transmission, 
suggestive of maternal inheritance of mutations in the mitochon-
drial ge nome, was found (1 7,18]. 
Not only have enzymatic methods clarified the biochemical basis 
of the human porphyrias bur latterly they have allowed several 
homozygous deficiency states, that affect chiefly the final steps of 
haem biosynthesis, to be characterized [19 -21]. It is therefore of 
great interest that Deybach and his colleagues have reported re-
cently a single patient with a homozygous deficiency of haem 
synthase (ferrochelatase) in whom both apparently normal parents 
showed partial enzymatic deficiency with elevated faecal and red 
ce ll protoporphyrin concentrations [22). The present study 'con-
firms the existence of several similar pedigrees in whom recessive 
transmission of protoporphyria has occurred. 
Further examination of the enzymatic activities in first-degree 
relatives of our patients with symptomatic protoporphyria shows 
that the zinc chelatase was below the mean control val ue in 17 of the 
18 parents of nine patients affected by the disorder. Only three of 
these parents had symptomatic protoporphyria. It is also note-
worthy that haem synthase activities in eight of nine unaffected 
siblings and six of seven fit offspring of affected individuals were 
below the mean control value. These observations suggest that EPP 
is not inherited as a dominant trait with or without variable pene-
trance and does not co-segregate in most instances in a simple man-
ner with deficiency of haem synthase activity. 
As previously noted in EPP patients, haem synthase determined 
by the zinc assay was less than 20% of the mean control value J1, 11]. 
This would not be expected ll1 an autosomal dom1l1ant dIsorder 
where the presence of a single normal allele should permit e~pres­
sion of half normal enzyme activIty . One pOSSible explanation of 
this finding might relate to the structural features of the ~oloen­
zyme; if the enzyme were multl~etlc, then a mutation affectmg one 
polypeptide sub-unit mIght dIsrupt assembly of the. quaternary 
structure in its active conformatIon and thus dIsproportionately Im-
pair enzymatic function. However, p~rification of ferrochelatase 
from rat, bovine, mouse, and chicken tIssues has not revealed con-
vincing evidence for a multimeric structure of the hol.o-enzyme 
[23]. In addition, we have found that the enzyme retams Its.actlVlty 
in the presence of high concentrations of salt, 0.05% sodlUm do-
decyl sulphate, and reducing agents.* . 
Most mitochondrial proteins are encoded m the nucleus and 
synthesized as precursors on pol yribosomes in the cytosol. These 
nascent proteins contain amino-terminal prese9uences that are nec-
essary for binding to specific recognition protems on the mitochon-
drial surface before they are imported into the organell e and pro-
cessed during maturation [24] . The products. of many. genes 
participate in the biogenesis of nuclear-encoded mltochondna~ pro-
teins and thus lesions in any bne of them may affect the actIvIty of 
enzymes destined to mature in this organel le. For example, non-al-
• Nunn AVW, Cox TM (unpublished results , 1988). 
THE J OURNAL OF INVESTIGATIVE DERMATOLOGY 
leli c mutations in the mitochondrial binding site could block trans-
location of haem synthetase to the inner mitochondrial membrane 
and dras tically reduce enzymatic function at its natural site of action. 
In particular, a single mutation that interfered with the processing 
of the nascent enzyme would impair the import of the aber~t 
polypeptide and thus, by blocking a limited number of Import Slt~ 
might also arrest the translocation of the normal component to Its 
destination in the inner mitochondrial membrane. 
Alternatively, a mutation disturbing a gene other than that di-
rectly involved in haem synthesis could conceivably result in a mi-
tochondrial defect that affected uptake and transport of substrates. A 
single mutation resulting in an altered lipid environment of ~he 
enzyme, which is known to depend on phospholipids for full acnv-
icy [23], might be expected to impair its function in situ . Howev~r 
since haem synthesis appears to be maintained and mltochondn al 
structure is normal in this disease, evidence for more generahzed 
mitochondrial defect is lacking [25,26] . 
In summary, our findings indicate a marked degree ofbiochemi-
cal heterogeneity in the pattern of inheritance of protoporphyna 
such that simple biochemical screening of family members does not 
in many instances allow prediction of disease transmission and pre-
cludes confident identification of carrier status. The profound defi-
ciency of enzyme activity in all affected individuals so far studied 
strongly suggests that the influence of more than one gene ~a:t be 
necessary for disease expression [9] but the existence of a dlsOllcr 
sub-group showing simple recessive inheritance might ~l1ow g~­
netic counseling in some circumstances. Further systematic anaJySlS 
of the genetic abnormalities in pedigrees showing different patterns 
of transmission may resolve these questions and shed light on the 
spectrum of defects responsible for this mitochondrial disorder in 
man. Such an analysis will require the use of specific probes to 
investigate the structure and biosynthesis of the mature haem 
synthase molecule. . 
We are gratejid 10 Dr. Nic!Jolas Barton of tile Galton Laboratory for i,tjonJlocil'( 
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The President of The American Academy of Dermatology, J. Graham Smith, Jr., M.D., has 
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menting the donated material with the evaluation for tax deduction purposes. The material will 
be matched with the "want list" from the various centers in need. Precise instructions on 
packaging and shipping procedures will be sent to the donor. 
Recipients and donors should contact John M. Shaw, M.D., 701 North -E- Street, Tacoma, 
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